Roadmap Targets Stroke Recovery With Personalized Rehab

 Not even having the goal of 100% recovery; we get biomarker crapola like this!

Roadmap Targets Stroke Recovery With Personalized Rehab

WASHINGTON -- An international task force co-led by a Georgetown University stroke expert has outlined a bold new roadmap for stroke recovery, positioning genetic and blood biomarkers to drive the next generation of precision neuro-rehabilitation and biotherapy. The framework aligns with Georgetown's strategic focus on advancing brain health and accelerating discoveries that restore function and independence after neurological injury.

The roadmap appeared August 19, 2026, in the International Journal of Stroke ("Molecular biomarkers in stroke recovery: Consensus-based core recommendations from the fourth Stroke Recovery and Rehabilitation Roundtable").

Most stroke recovery is facilitated by either occupational, physical or speech therapy. The general consensus in the field is that all of these are beneficial and more is better. However, it is still not known how much is optimal, when is the best time to deliver therapy and which method of therapy delivery is best. As there are also real challenges in how to measure the effects of these interventions on brain plasticity in real time, molecular biomarkers could help answer such questions.

More importantly, there is now only a basic understanding of how the human brain repairs itself after a stroke. Gaining this knowledge is crucial to developing effective biotherapeutics for the recovery phase of stroke -- a time period in which there are currently no proven treatments outside of occupational, physical and speech therapy.

A competent? researcher would know of the recovery protocol that Pedro Bach-y-Rita  used to recover fully back in 1958 with only a partial brain! But you don't have competent anything in stroke! 

"There are major discoveries waiting to be made that will tell us how the human brain adapts to injury and repairs itself after a stroke. These discoveries have the potential to be extremely useful in developing new medicines or therapies that will reduce the disability that many suffer after a stroke," says Matthew A. Edwardson, MD, associate professor of neurology and rehabilitation medicine at Georgetown University School of Medicine, and a member of the stroke team at MedStar Georgetown University Hospital. "Notably, the reason these discoveries have not yet been made is that most earlier stroke recovery studies were at single centers with a small number of patients with blood collected at a single time point after a stroke, or with non-specific methods of measuring stroke recovery."

Edwardson, who co-chaired the task force with Robynne Braun, MD, PhD, from the University of Maryland, also notes that much larger studies with multiple blood samples collected chronologically at the same time points for each patient, using the same outcome measures, are necessary to achieve the statistical power needed to make much more informed choices in the future.

Given that molecular innovations have dramatically advanced fields like cardiovascular disease, leading to individualized antiplatelet regimens and targeted lipid-lowering therapies, it is notable that molecular research in clinical stroke recovery has lagged behind.

Edwardson says there are multiple reasons for this lag:

· Stroke recovery studies are difficult to conduct logistically. For most acute studies, data is collected at hospital admission; after discharge the patient is called 90 days later to get outcomes over the phone. In contrast, a recovery study might require a patient to be seen again at 1 month, 3 months and 6 months after a hospital discharge. This follow-up might occur at home, at a nursing facility, or at an inpatient rehabilitation facility during those various times, so it is more challenging to collect study data at these varied locations.

· Recovery studies have traditionally been expensive if they employ a rehabilitation intervention because a therapist needs to deliver the care over multiple weeks.

· There has been limited pharmaceutical industry investment in the recovery phase of stroke, so there have been few large studies in this arena.

A central pivot of the new taskforce consensus is a refreshed definition of Stroke Recovery Biomarkers. Rather than focusing solely on predicting a patient's ultimate outcome – recovery as a product -- the taskforce prioritizes understanding the underlying biology -- recovery as a process.

The taskforce made numerous suggestions to advance the field, including:

 Harmonizing molecular biomarkers in stroke recovery studies to collect blood at the same time points and collect the same outcome measures, including those for specific deficits like arm/leg weakness, speech/language disorders and cognition problems. "The crucial next step would be the analysis of the data in a rigorous manner, including replication across patient groups that are comprised of different geographic populations and/or ethnic backgrounds," Edwardson says

· Larger, international studies are needed because in other fields of medicine major discoveries using genomics did not occur until sample sizes were in the thousands. "This will require investment: funding for these larger studies, infrastructure for biorepositories to store samples in different continents, and expertise to help guide interested researchers who want to participate," he explains.

· A key principle is that recovery biomarkers should not be used to deny access to care. The taskforce discovered that upon surveying other experts in the field, many are worried that a molecular biomarker predicting that certain patients are likely to have poor recovery could be used against a patient to allow an insurance company to deny them access to rehabilitation care. "The taskforce wants to stress that molecular biomarkers should not be used in this manner to ration resources, but rather to learn more about the molecular biology of a stroke to develop new treatments," Edwardson says.

Edwardson's work in tailoring rehabilitation is ongoing. A member of the Center for Brain Plasticity and Recovery at Georgetown University and MedStar National Rehabilitation Hospital, Edwardson and his Georgetown colleagues recently received a Thomas A. Reynolds III Return to Function Challenge Grant for a related study titled "Circulating Molecular Biomarkers to Monitor Cellular and Organ Remodeling During Stroke Recovery."

"The identification of a promising pipeline of biomarkers is key in brain health and stroke recovery," Edwardson says. "The next step is to rigorously validate them in larger patient populations so they can become the foundation for a new era of precision stroke rehabilitation,"

This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.